Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar)
Highlights: Etana is a biopharmaceutical company based in Indonesia that specializes in researching, producing, and commercializing biological therapies for the Southeast Asian market. Its facilities have the capability to produce biological therapeutics with halal certification from the Indonesian Ulema Council (MUI). In 2022, Innovent Biologics, Inc. China, and Etana Biotechnologies Indonesia jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen®, a recombinant humanized anti-VEGF monoclonal antibody drug for five indications, including metastatic colorectal cancer (mCRC), locally recurrent or metastatic triple-negative breast cancer (mTNBC), advanced, metastatic, or recurrent non-small cell lung cancer (NSCLC), epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC), and cervical cancer (CC). Under the current licensing agreement with Innovent, Etana will commercialize Bevagen® in Indonesia. Bevagen® has the potential to be the first Chinese antibody drug to be produced and marketed locally in Southeast Asia.
Link to Original Article